Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Weisberg, Ellen ^a   Liu, Qingsong ^a   Zhang, Xin ^a   Nelson, Erik ^a   Sattler, Martin ^a   Liu, Feiyang ^b   Nicolais, Maria ^a   Zhang, Jianming ^a   Mitsiades, Constantine ^a   Smith, Robert W ^a   Stone, Richard ^a   Galinsky, Ilene ^a   Nonami, Atsushi ^a   Griffin, James D ^a   Gray, Nathanael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AT 7867; KIN 001 102; MIDOSTAURIN; PROTEIN KINASE B INHIBITOR; QUIZARTINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; PRIMARY TUMOR; STROMA CELL; TUMOR MICROENVIRONMENT;

APOPTOSIS; BENZOTHIAZOLES; BONE MARROW CELLS; CELL COMMUNICATION; CELL CYCLE; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; STAUROSPORINE; STROMAL CELLS;

EID: 84874322664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056473     Document Type: Article

References (29)

1. Kumagai M, Manabe A, Pui CH, Behm FG, Raimondi SC, et al. (1996) Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 97: 755-760.
2. Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, et al. (2008a) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 7: 1121-9.
3. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, et al. (2009) FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 12: 81-9.
4. Stirewalt DL, Radich JP, (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3: 650-65.
5. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, et al. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitors PKC412. Cancer Cell 1: 433-443.
6. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, et al. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114: 2984-2992.
7. Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, et al. (2012a) Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors. Leukemia 26: 2233-44.
8. Bendall LJ, Daniel A, Kortlepel K, Gottlieb DJ, (1994) Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 22: 1252-60.
9. Mudry RE, Fortney JE, York T, Hall BM, Gibston LF, (2000) Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 96: 1926-32.
10. Garrido SM, Appelbaum FR, Willman CL, Banker DE, (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29: 448-57.
11. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV, (1996) Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol 92: 97-103.
12. Nefedova Y, Landowski TH, Dalton WS, (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17: 1175-82.
13. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, et al. (1997) Two acute monocytic leukemia (AML-M5a) cell lines (MOLM13 and MOLM14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11: 1469-77.
14. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG, (2003) FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17: 120-4.
15. Kimbrel EA, Davis TN, Bradner JE, Kung AL, (2009) In vivo pharmacodynamic imaging of proteosome inhibition. Mol Imaging 8: 140-147.
16. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, et al. (2003) Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-83.
17. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, et al. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99: 310-318.
18. Chou T-C, Talalay P, (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22: 27-55.
19. Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, et al. (2008b) Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 111: 3723-34.
20. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, et al. (2010) Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 25: 2100-2109.
21. Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, et al. (2012b) Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26: 985-90.
22. Gu TL, Nardone J, Wang Y, Loriaux M, Villen J, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One. 6: e19169.
23. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, et al. (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Research 67: 684-94.
24. Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, et al. (2004) Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 18: 1964-70.
25. Gaundar SS, Bradstock KF, Bendall LJ, (2009) p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 8: 2975-83.
26. Piloto O, Wright M, Brown P, Kim KT, Levis M, et al. (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 109: 1643-1652.
27. Siendones E, Barbarroja N, Torres LA, Buendia P, Velasco F, et al. (2007) Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol. 25: 30-7.
28. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, et al. (2006) Simultaneous inhibition of PDK1/Akt and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 666: 3737-46.
29. Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, et al. (2012) Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. Oncoimmunology 1: 618-629.